Company news
Citius Pharmaceuticals, Inc. news in 2020
Citius Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.
Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap
December 8, 2020
Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components
November 29, 2020
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)
October 6, 2020
Citius's Mino-Lok trial sites resupplied with registration batch product
September 29, 2020
Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial
September 28, 2020
Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok®
September 21, 2020
Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance
September 14, 2020
Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap
August 25, 2020
Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
August 9, 2020
Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering
August 4, 2020
Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult
August 3, 2020
Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19
July 21, 2020
Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President
July 13, 2020
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
July 12, 2020
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
June 25, 2020
Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy
June 1, 2020
Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®
May 25, 2020
Citius Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
May 17, 2020
Citius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
May 13, 2020
Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 12, 2020
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19
April 26, 2020
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
March 31, 2020
Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris
March 25, 2020
Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
February 3, 2020
Decks in 2020
- Investor Presentation (August 2020)
Investor deck · 36 slides · Aug 26, 2020
- Investor Presentation (April 2020)
Investor deck · 39 slides · Apr 29, 2020
- Investor Presentation (January 2020)
Investor deck · 37 slides · Jan 22, 2020